1. FDA. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Rockville: Division of Metabolism and Endocrine Drug Products; 1994. Available from:
http://citeseerx.ist.psu.edu/viewdoc/download;jsessionid=EAA6005F8C1A1FB056C2CF3052F27ECF?doi=10.1.1.230.2918&rep=rep1&type=pdf
. Accessed 17 Oct 2019.
2. Committee for Medicinal Products for Human Use. Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. European Medicines Agency; 2006. Available from:
https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-treatment-primary-osteoporosis_en.pdf
. Accessed 17 Oct 2019.
3. Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab. 2007;92(8):3076–81.
4. Blake GM, Fogelman I. Long-term effect of strontium ranelate treatment on BMD. J Bone Miner Res. 2005;20(11):1901–4.
5. Nielsen SP, Slosman D, Sorensen OH, Basse-Cathalinat B, De Cassin P, Roux CR, et al. Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J Clin Densitom. 1999;2(4):371–9.